mynth
← DATABASE
09/2025100%

DCC Healthcare acquired by INVESTCorporate

UNITED KINGDOM Life Sciences / Pharma & Biotech / CDMO EV £1–10bn

Context

InvestIndustrial finalized the acquisition of DCC Healthcare Limited from the London-listed group DCC plc. This transaction is a strategic corporate carve-out designed to simplify DCC plc's operations, allowing the group to focus resources on its largest and most profitable Energy division. The proceeds from the sale are earmarked for distribution to DCC shareholders. The deal received regulatory approval from the European Commission.

DCC Healthcare, which reported an EBITDA margin of [members only] in 2024, is valued in this transaction at an EV/EBITDA multiple of [members only].

-> Deep-dive in Healthcare & Pharma market trends

Target

DCC Healthcare is a leading healthcare business providing products and services to health and beauty brand owners and healthcare providers. It operates as a CDMO (Contract Development and Manufacturing Organization) and distributes medical devices and pharma products.

Ent. Value

£1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

[members only]

EV / EBIT

10x–18x

Historical Financials (GBP)

Year
Rev
EBITDA
EBIT
2024
£450–900M
[members only]
£50–100M
2023
£450–900M
[members only]
£50–100M

Other operations with INVESTCorporate

Other operations with INVESTCorporate
DateAcquirerTargetCountrySector
10/2026INVESTCORPORATECONNECTIFSPAINMarTech
11/2025INVESTCORPORATETREEHOUSE FOODSCANADAFood Products

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
11/2025PFIZERMETSERAUNITED STATESR&D Biotech
10/2025PUBLIC MARKETS (IPO)OTTOBOCKGERMANYImplants & Prosthetics
09/2025CAPVEST PARTNERSSTADAGERMANYGenerics / Labs
09/2025HEARTLAND FOOD PRODUCTSSLIMFASTUNITED STATESNutrition & Dietary Supplements
09/202521 INVEST / BNP PARIBAS BNL EQUITY / FONDO ITALIANO DI INVESTIMENTOELSE SOLUTIONSITALYDiagnostic Equipment
09/2025CREDIT MUTUEL EQUITY / EURAZEO / BPIFRANCE / BNP PARIBAS DEVELOPPEMENTPROTEORFRANCEImplants & Prosthetics
08/2025LGT CAPITAL PARTNERSNEMERAFRANCEMedical Consumables
08/2025PAI PARTNERSINNOVAD GROUPBELGIUMAnimal Health
08/2025WARBURG PINCUSSEBIAFRANCEDiagnostic Equipment
08/2025TERUMOORGANOXUNITED KINGDOMMedical Devices

REFERENCES

Valuation range: EV £1–10bn

Revenue range: £450–900M

EV/Revenue range: 1x - 3x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DCC Healthcare by INVESTCorporate are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers INVESTCorporate’s acquisition of 100% of DCC Healthcare, a British company specialised in Pharma & Biotech, in 2025.

How was the acquisition of DCC Healthcare by INVESTCorporate valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the £1–10bn band and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What was DCC Healthcare’s revenue at the time of the deal?

At the time of the transaction, DCC Healthcare’s annual revenue was estimated within the £450–900M range (FY 2024). Detailed financial figures are available to members.

What sources support the information on this transaction?

Data on this transaction was compiled from the official corporate announcement published by the parties, combined with independent reporting from specialized financial and M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.